Elimination of @entity1522 in XXXX .

@entity1 @entity2226 @entity1522 @entity563 @entity2228 @entity368 @entity535 @entity3793 @entity7222 @entity1853 @entity376 @entity1434 @entity810 @entity367 @entity4857 @entity1521 @entity815 @entity669 @entity2574 @entity1889
Plasma @entity535 concentrations and the elimination of parenterally administered @entity1522 were investigated in 12 @entity1 with nonhypercatabolic @entity810 . A distinctive plasma @entity535 pattern could be observed: plasma concentrations of @entity815 and @entity1853 were increased, those of @entity4857 and @entity368 decreased. Of the nonessential @entity1522 , @entity1434 , @entity2226 und @entity669 had elevated but none of them reduced plasma concentrations. The elimination of @entity1522 was evaluated in a monocompartment model after bolus injection of an @entity535 solution containing essential and nonessential @entity1522 . Pharmacokinetic parameters of 17 @entity1522 were calculated. The mean elimination half-time was raised by 25%. The elimination half-time of @entity815 , @entity1853 , @entity367 , @entity1521 and @entity7222 was increased. @entity3793 was the only @entity535 with--however insignificantly--accelerated elimination from the intravascular compartment. The total clearance rate and total transfer rate was not altered (107 and 97% of normal, respectively). The clearance of @entity1889 , @entity376 , @entity563 , @entity2228 and @entity3793 was increased, of @entity4857 , @entity815 , @entity367 and to a minor degree of @entity1853 was decreased. The transfer rate of @entity1853 , @entity376 , @entity2228 was elevated, of @entity4857 , @entity2574 , @entity367 and @entity7222 reduced. The demonstration of these pronounced alterations of @entity535 elimination in @entity810 may have major consequences in parenteral @entity535 therapy.
